icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
An Open-Label Study to Evaluate the Efficacy and Safety of Co-Formulated Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults with Chronic HCV Genotype 4 Infection in Egypt (AGATE-II)
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Wahid Doss1, Gamal Esmat2, Roula B Qaqish3, Imam Waked4, Gamal Shiha5, Ayman Yosry2, Jennifer King3, Coleen Hall3, Niloufar Mobashery3
1National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt; 2Cairo University, Cairo, Egypt; 3AbbVie Inc., North Chicago, Illinois, USA; 4National Liver Institute, Menoufiya, Egypt; 5Egyptian Liver Research Institute and Hospital (ELRIAH), Dakahliah, Egypt

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif